Celgene asserts its REVLIMID® patents against Dr. Reddy’s Laboratories under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Dr. Reddy's Laboratories in several Hatch-Waxman litigation matters involving DRL's proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
Celgene Corporation v. Dr. Reddy's Laboratories, Ltd., et al., Nos. 2-16-cv-07704, 2-17-cv-05314, & 2-18-cv-06378 (D.N.J.)